KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Total Non-Current Liabilities: 2013-2025

Historic Total Non-Current Liabilities for Halozyme Therapeutics (HALO) over the last 13 years, with Sep 2025 value amounting to $1.6 billion.

  • Halozyme Therapeutics' Total Non-Current Liabilities rose 1.27% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 1.27%. This contributed to the annual value of $1.6 billion for FY2024, which is 2.06% up from last year.
  • Halozyme Therapeutics' Total Non-Current Liabilities amounted to $1.6 billion in Q3 2025, which was up 0.13% from $1.6 billion recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Total Non-Current Liabilities registered a high of $1.7 billion during Q1 2025, and its lowest value of $896.2 million during Q1 2021.
  • Its 3-year average for Total Non-Current Liabilities is $1.6 billion, with a median of $1.6 billion in 2024.
  • In the last 5 years, Halozyme Therapeutics' Total Non-Current Liabilities surged by 116.86% in 2021 and then decreased by 1.66% in 2023.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Total Non-Current Liabilities stood at $906.9 million in 2021, then spiked by 80.72% to $1.6 billion in 2022, then decreased by 1.66% to $1.6 billion in 2023, then rose by 2.06% to $1.6 billion in 2024, then grew by 1.27% to $1.6 billion in 2025.
  • Its Total Non-Current Liabilities was $1.6 billion in Q3 2025, compared to $1.6 billion in Q2 2025 and $1.7 billion in Q1 2025.